Amalie Kjær Andresen is a PhD student at the Technical University of Denmark (DTU), Lyngby, working within the Pharmaceutical Technology group led by Line Hagner Nielsen. Her research centers on the development of nanoparticulate formulations for the eradication of Pseudomonas aeruginosa biofilms, with a particular focus on localized delivery of antibiotics and antibacterial agents for the treatment of chronic rhinosinusitis and chronic wounds via nasal and topical delivery.
In addition to formulation development, her research also explores the establishment of methods to quantify the efficacy of these systems in both static and dynamic biofilm models.
She holds a master’s degree in pharmacy (Cand.scient.pharm) from the University of Copenhagen, providing her with a comprehensive understanding of the pharmaceutical development pipeline, from drug discovery to patient compliance, as well as a broad perspective on disease pathology and treatment strategies.
During her master’s degree she gained a broad understanding within the field of drug delivery to the brain and overcoming the blood-brain-barrier with a focus on quantification techniques of in vivo samples.
